Skip to content
Open access

Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy

Sep 2026 · bioRxiv · 0 citations · 31 references
Biology

TL;DR

A strategy to identify novel CDK4 inhibitors targeting the CDK4-Cyclin D1 protein-protein interaction, a key determinant of CDK4 activation, and diophenic emerged as the lead candidate, demonstrating consistent antiproliferative activity across multiple GBM and epithelial cancer models.

Read PDF

Similar papers

Review Aug 2026

Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact.

The molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis, its role in super-enhancer-driven oncogenic programs, and the mechanisms by which CDK9 inhibition promotes apoptosis, epigenetic derepression, and tumor microenvironment remodeling are summarized.

Ti-Yao Liu, Zhongran Liu, Wen-Jing Wei et al. · 0 citations
Review Open access Sep 2026

A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer

It is demonstrated that MNK1/2 inhibition synergizes with CDK4/6 blockade suppresses TNBC cell growth, a synergy also observed in another independent TNBC cell line (SUM159) using a broader G1/S CDK (CDK2/4/6) inhibitor.

Qi-Yun Deng, Mehdi Amiri, A. Moshari et al. · 0 citations
Review Open access Aug 2026

Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming

A candidate biomarker-informed framework that integrates tumor-cell escape with cytokine, immune, stromal, vascular, and metabolic remodeling and summarizes emerging therapeutic strategies is proposed, providing a translational basis for testing state-informed and sequence-aware therapeutic strategies.

Yu-Han Tang, Ying-Ze Zhu, Shao-Chun Liu et al. · 0 citations
Open access Sep 2026

CGP60474, a novel MITD1-targeted inhibitor for bladder cancer progression via CDK4/cyclin D1 pathway modulation

It is shown that MITD1 is elevated in bladder cancer and associated with poor patient prognosis, and it is found that MITD1 drives cancer progression by interacting with the CDK4/cyclin D1 complex to regulate the cell cycle.

Suo-Shi Jing, En-Guang Yang, Xin-Yu Zhang et al. · 0 citations
Sep 2026

Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2.

CDK2 is a critical regulator of cell-cycle progression and is an attractive therapeutic target for cancers characterized by dysregulated cyclin E1 signaling. Despite this biological rationale, CDK2 has historically been challenging to target due to the difficulty of achieving selectivity over related CDK isoforms, part...

Ken Mukai, Brandon R. Smith, Qin-Da Ye et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.